| Literature DB >> 28540578 |
Abstract
CLINICAL ISSUE: The reduced corneal mechanical stability in keratoconus and similar collagen diseases can lead to a progressive and irregular corneal shape and decrease of visual acuity. DIAGNOSTICS: A progression of keratectatic diseases can be shown with corneal topography. TREATMENT: Keratoconus can be treated by photo-oxidative cross-linking of the corneal collagen. In order to achieve a high absorption of irradiation energy in the cornea, riboflavin at a concentration of 0.1% and UVA light at a wavelength of 370 nm corresponding to the relative maximum absorption of riboflavin (vitamin B2) are used. Evidence for corneal cross-linking are the increase of biomechanical stiffness, the increased resistance against enzymatic degradation, a higher shrinkage temperature, a lower swelling rate and an increased diameter of collagen fibers. The currently available data demonstrate that the therapeutic cross-linking procedure is safe when respecting the important theoretical and clinical parameters and that a progression of the keratoconus can be avoided. In 80% of cases an average levelling of the curvature of approximately 2 dpt can be achieved, which leads not only to stabilization but also to an increase in visual acuity of approximately 1.2 lines. ASSESSMENT: In a Cochrane review from 2015 publications about complications and results were reviewed. Complication rates ranged from 1-10% depending on the initial situation, comorbidities and stage of the keratoconus. The most important complications are early epithelial wound healing problems as well as extremely rare perforations. PRACTICAL RECOMMENDATIONS: Corneal cross-linking is a well-established and safe procedure but is not free of complications.Entities:
Keywords: Collagen diseases; Cornea; Cross-linking; Keratoconus; Riboflavin
Mesh:
Substances:
Year: 2017 PMID: 28540578 DOI: 10.1007/s00347-017-0511-1
Source DB: PubMed Journal: Ophthalmologe ISSN: 0941-293X Impact factor: 1.059